XML 26 R16.htm IDEA: XBRL DOCUMENT v3.25.2
Earnings per share
 6 Months Ended
Jun. 30, 2025
Earnings Per Share [Abstract]  
Earnings per share Earnings per share
The Company is required to present basic earnings per share and diluted earnings per share ("EPS") in its Consolidated Statements of Operations. Basic EPS amounts are computed by dividing net income by the weighted average number of shares of common stock outstanding. Diluted EPS reflects additional shares of common stock that would have been outstanding if potentially dilutive shares of common stock had been issued, as well as any adjustment to income that would result from the assumed issuance. Potential shares of common stock that may be issued by the Company relate to outstanding unvested RSAs and RSUs granted to directors and employees, and stock options. The dilutive effect resulting from these potential shares is determined using the treasury stock method. The Company is also required to provide a reconciliation of the numerator and denominator used in the computation of both basic and diluted EPS.
On March 20, 2025, in connection with the $57.75 million Private Placement, the Company issued 60,400,106 shares of Common Stock and 90,832 shares of Series A Preferred Stock, which are convertible into 7,266,560 shares of Common Stock. In addition, as part of the Private Placement, on March 20, 2025, the Company’s amendments to (i) 6.25% Fixed to Floating Subordinated Note due June 30, 2028 (the “Subordinated Note”), and (ii) 8.5% Fixed Rate Senior Notes Due 2026 (the “Senior Notes” and together with the Subordinated Note, the “Notes”) became effective and noteholders converted approximately $7.0 million of the aggregate principal amount of the Notes into 9,333,334 shares of Common Stock. The amendments to Subordinated Note and Senior Notes allow for interest to be paid-in-kind, increasing the principal amount, while the Senior Notes amendment also extends the maturity date to April 15, 2028 and adjusts the interest rate in 2026.
On May 13, 2025, two noteholders of the Senior Notes converted $1.90 million of the aggregate principal and interests of the Notes into 2,529,275 shares of Common Stock.
On June 3, 2025, the Company entered into a Securities Purchase Agreement with accredited investors, facilitating a registered direct offering. The Company issued and sold 8,524,160 shares of its common stock, $0.01 par value per share, at a price of $1.25 per share. The net proceeds of the offering was approximately $10.47 million after estimated expenses.
These transactions affect the weighted average number of shares outstanding.
The following table summarizes the computation of basic and diluted loss per share for the three and six months ended June 30, 2025 and 2024, including the effects of the Private Placement.
(Net loss in thousands)Three Months Ended June 30,Six Months Ended June 30,
2025202420252024
Basis loss per share:
Net loss attributable to Common shareholders$(5,001)$(3,081)$(7,778)$(3,380)
Divided by:
Weighted average shares outstanding78,123,0953,976,07345,885,4683,976,073
Basic loss per share of common stock$(0.06)$(0.77)$(0.17)$(0.85)
Diluted loss per share:
Net loss attributable to Common shareholders$(5,001)$(3,081)$(7,778)$(3,380)
Weighted average shares outstanding78,123,0953,976,07345,885,4683,976,073
Effect of potentially dilutive restricted shares of common stock— (1)— (2)— (3)— (4)
Divided by:
Weighted average diluted shares outstanding78,123,0953,976,07345,885,4683,976,073
Diluted loss per share of common stock$(0.06)$(0.77)$(0.17)$(0.85)
(1)
The weighted average diluted shares outstanding does not include 4,597,710 anti-dilutive restricted shares of common stock for the three months ended June 30, 2025.
(2)
The weighted average diluted shares outstanding does not include 8,695 anti-dilutive restricted shares of common stock for the three months ended June 30, 2024.
(3)
The weighted average diluted shares outstanding does not include 5,119,740 anti-dilutive restricted shares of common stock for the six months ended June 30, 2025.
(4)
The weighted average diluted shares outstanding does not include 4,330 anti-dilutive restricted shares of common stock for the six months ended June 30, 2024.